Valuation report: Aegerion (AEGR)

Valuation report: Aegerion (AEGR)

July 4, 2014.

I’ll start the first valuation report of Iber Biotech with Aegerion (NASDAQ: AEGR). The company markets Juxtapid, a drug intended for the treatment of homozygous familial hypercholesterolemia (HoFH), an ultra-rare disease that produces extremely high blood cholesterol levels leading to a very high risk of heart attack and/or stroke.

[Read more...]